Buy DPAI Cas 76149-15-0

DPAI, also known as 4-(N,N-dipropylaminoethyl)indole (4-DPAEI), 2-desoxo-2-ene-ropinirole, or BD-179, is a dopamine receptor agonist and partial ergoline closely related to the clinically used dopamine receptor agonist and antiparkinsonian agent ropinirole.^[1]^[2]^[3]^[4]

It has a delayed onset of effects and weak actions in vitro, suggestive that it may be a metabolically activated prodrug via 6-hydroxylation into its metabolite 6-HO-DPAI (TL-350).^[5]^[2]^[3]^[6]^[4] The drug is said to be a highly selective agonist of presynaptic dopamine autoreceptors, with little or no activity at postsynaptic dopamine receptors.^[1]^[7]^[8]^[9] It dramatically reduces dopamine release in the caudate nucleus, produces hypolocomotion, and strongly suppresses prolactin secretion in rodents.^[1]^[8]^[9]^[10]^[11] No effects of DPAI on serotonin receptors have been reported, at least as of 1982.^[12]

DPAI was first described in the scientific literature by 1980.^[3]^[1] It was developed independently by David E. Nichols and colleagues and by another group of researchers.^[11] Analogues of DPAI in which its propyl groups have been replaced with other alkyl groups such as methyl or ethyl groups have also been studied.^[4]^[11]